Alector, Inc. (NASDAQ:ALEC) Receives $4.17 Average PT from Analysts

Key Points

• Alector, Inc. has received a consensus rating of "Hold" from seven research firms, with two analysts recommending a sell and four a buy.
• The company's stock price has fluctuated between a 1 year low of $0.87 and a high of $6.37, currently opening at $2.40.
• Alector reported a quarterly earnings of ($0.30) EPS, surpassing expectations and generating revenue of $7.87 million, significantly higher than analysts' predictions.

Shares of Alector, Inc. (NASDAQ:ALEC - Get Free Report) have received a consensus recommendation of "Hold" from the seven research firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $4.1667.

Several equities analysts recently commented on ALEC shares. HC Wainwright upped their price target on shares of Alector from $7.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Wall Street Zen upgraded shares of Alector from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Mizuho upgraded shares of Alector from a "neutral" rating to an "outperform" rating and upped their price target for the company from $2.50 to $3.50 in a research note on Monday, July 28th.

Alector Stock Performance

Shares of NASDAQ:ALEC traded up $0.24 on Thursday, hitting $2.59. The company had a trading volume of 1,749,954 shares, compared to its average volume of 1,584,005. Alector has a 1-year low of $0.87 and a 1-year high of $6.37. The stock has a market cap of $262.13 million, a price-to-earnings ratio of -2.23 and a beta of 0.99. The stock has a 50 day moving average price of $1.83 and a 200 day moving average price of $1.50. The company has a current ratio of 3.78, a quick ratio of 3.78 and a debt-to-equity ratio of 0.13.

Alector (NASDAQ:ALEC - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. The firm had revenue of $7.87 million for the quarter, compared to the consensus estimate of $2.76 million. Alector has set its FY 2025 guidance at EPS. Analysts expect that Alector will post -1.88 EPS for the current year.

Insiders Place Their Bets

In related news, Director Paula Hammond sold 14,000 shares of the company's stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the completion of the sale, the director owned 74,909 shares of the company's stock, valued at $176,785.24. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 9.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new stake in Alector during the 4th quarter valued at approximately $18,324,000. 5AM Venture Management LLC acquired a new stake in shares of Alector during the 4th quarter worth approximately $1,882,000. Acadian Asset Management LLC grew its position in shares of Alector by 50.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,170,388 shares of the company's stock worth $3,033,000 after buying an additional 729,727 shares during the period. TD Asset Management Inc grew its position in shares of Alector by 483.3% during the 2nd quarter. TD Asset Management Inc now owns 651,738 shares of the company's stock worth $912,000 after buying an additional 540,000 shares during the period. Finally, Vestal Point Capital LP acquired a new stake in shares of Alector during the 1st quarter worth approximately $621,000. Institutional investors own 85.83% of the company's stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.